| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
The hardware advantages of (Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH The internal standard for prorelin [1]. Add 100 µL of the catalyst sample and 10 µL of the 200 ng/mL (Des-Gly10,D-2) In two volumes of 500 µL each, add frozen acetonitrile to the solution in (1). Third, stir for ten minutes at 2500 rpm. (4) 4°C/12,500 rpm (5) Incorporate 100 µL of a 0.1% formic acid aqueous solution/ethyl iodide: 90/10 (v/v) solution after transferring the supernatant to a centrifuge tube and drying it under ozone at 35°C. (6) The Orbitrap Exploris 480 mass spectrometer of Thermo Scientific was linked to the Vanquish UPLC system of the same company. at 40°C and separated using a Waters Acquity UPLC HSS T3 column (2.1 × 100 mm, 1.8 µm). (7) The aqueous solution containing 0.1% phosphoric acid is the mobile phase A, while the 0.1% phenyl acetone solution is the mobile phase B. From 95%, the gradient is present. Phase A should be used first, then after five minutes, reduce to 10%, and last for 0.5 minutes at a consistent level. Re-evaluate after six minutes and go back to the column with 95% mobile phase A. (8) In the positive ion mode, the material is electrosprayed ionized at 3500V. Southern leuprolide is next, with m/z 605.3275, while internal standard is m/z 584.3052. 30 seconds. Apply the data analysis software Xcalibur (version 4.4).
|
|---|---|
| ln Vivo |
In both gonadized and non-gonadized patients, (Des-Gly10,D-Ala6,Pro-NHEt9)-LHRH (2 µg/kg; i.p.; single dosage) markedly elevated gland-related anxiety behaviors [2]. When paired with Ainil (3 mL/kg), Gly10, D-Ala6, Pro-NHEt9)-LHRH (50 µg; single dosage) enhanced post-fertilization fertility and avoided cyclic mortality in cows [3].
|
| References |
|
| Molecular Formula |
C56H78N16O12
|
|---|---|
| Molecular Weight |
1167.34
|
| Exact Mass |
1166.6
|
| CAS # |
52435-06-0
|
| Related CAS # |
Alarelin Acetate;79561-22-1
|
| PubChem CID |
5484741
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.33
|
| Hydrogen Bond Donor Count |
15
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
84
|
| Complexity |
2320
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CCNC([C@@H]1CCCN1C([C@@H](NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H]2CCC(N2)=O)=O)CC3=CN=CN3)=O)CC4=CNC5=CC=CC=C45)=O)CO)=O)CC6=CC=C(O)C=C6)=O)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)=O
|
| InChi Key |
QLGKMLRGKPKGKI-MUVLZESKSA-N
|
| InChi Code |
InChI=1S/C56H78N16O12/c1-5-60-54(83)45-13-9-21-72(45)55(84)39(12-8-20-61-56(57)58)66-50(79)40(22-30(2)3)67-47(76)31(4)64-49(78)41(23-32-14-16-35(74)17-15-32)68-53(82)44(28-73)71-51(80)42(24-33-26-62-37-11-7-6-10-36(33)37)69-52(81)43(25-34-27-59-29-63-34)70-48(77)38-18-19-46(75)65-38/h6-7,10-11,14-17,26-27,29-31,38-45,62,73-74H,5,8-9,12-13,18-25,28H2,1-4H3,(H,59,63)(H,60,83)(H,64,78)(H,65,75)(H,66,79)(H,67,76)(H,68,82)(H,69,81)(H,70,77)(H,71,80)(H4,57,58,61)/t31-,38?,39+,40+,41+,42+,43+,44?,45+/m1/s1
|
| Chemical Name |
N-[(2S)-1-[[(2S)-1-[[1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
|
| Synonyms |
AY 25,205; AY-25,205; Surfagon
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8566 mL | 4.2832 mL | 8.5665 mL | |
| 5 mM | 0.1713 mL | 0.8566 mL | 1.7133 mL | |
| 10 mM | 0.0857 mL | 0.4283 mL | 0.8566 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
